Congratulations To

HAIXI PHARMA (Stock Code: 2637.HK)

On The Successful IPO On The Main board Of The HKEX!

COMPANY PROFILE

Fujian Haixi Pharmaceuticals Co Ltd is a China-based company principally engaged in the research, development, production, and sales of generic drugs and innovative drugs. The Company’s main products include Anbili, Haihuitong, Ruiantuo and Saixifu. The Company’s products are mainly used in digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases, inflammatory diseases, oncology, ophthalmology, respiratory diseases and others. The Company mainly operates its businesses in the domestic market.

(Source: http://www.hkex.com.hk/）

CR SWCS Team is honoured to serve as

HAIXI PHARMA’s Joint Company Secretary,

committed to ensuring governance,

compliance, and sustained growth.